Related references
Note: Only part of the references are listed.Renal Transplantation in Systemic Amyloidosis - Importance of Amyloid Fibril Type and Precursor Protein Abundance
J. H. Pinney et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature
Judith Payet et al.
LEUKEMIA & LYMPHOMA (2013)
Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis
Maria V. Irazabal et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Autologous stem cell transplant for light chain deposition disease: Incorporating bortezomib to the induction therapy
Victor H. Jimenez-Zepeda et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey
Benjamin Terrier et al.
BLOOD (2012)
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
Joseph R. Mikhael et al.
BLOOD (2012)
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
Christopher P. Venner et al.
BLOOD (2012)
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
Nelson Leung et al.
BLOOD (2012)
High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease
D. Telio et al.
BONE MARROW TRANSPLANTATION (2012)
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease
A. Brioli et al.
BONE MARROW TRANSPLANTATION (2012)
Ten-Year Survival After Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis
Stefan Cordes et al.
CANCER (2012)
Renal Monoclonal Immunoglobulin Deposition Disease: A Report of 64 Patients from a Single Institution
Samih H. Nasr et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease
Natalia Tovar et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone
Wolfram Poenisch et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The cryoglobulinaemias
Manuel Ramos-Casals et al.
LANCET (2012)
Immunotactoid glomerulopathy: clinicopathologic and proteomic study
Samih H. Nasr et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure
Helen Gharwan et al.
MEDICAL ONCOLOGY (2012)
Differences in Immunoglobulin Light Chain Species Found in Urinary Exosomes in Light Chain Amyloidosis (AL)
Marina Ramirez-Alvarado et al.
PLOS ONE (2012)
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
Maria Teresa Cibeira et al.
BLOOD (2011)
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
Donna E. Reece et al.
BLOOD (2011)
Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease
Karthik Ramasamy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Proliferative Glomerulonephritis with Monoclonal IgG Deposits Recurs in the Allograft
Samih H. Nasr et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Glomerulonephritis With Isolated C3 Deposits and Monoclonal Gammopathy: A Fortuitous
Frank Bridoux et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Patterns of Noncryoglobulinemic Glomerulonephritis with Monoclonal Ig Deposits: Correlation with IgG Subclass and Response to Rituximab
Elsa Guiard et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Outcome in Renal AL Amyloidosis After Chemotherapy
Jennifer H. Pinney et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Kidney dysfunction during lenalidomide treatment for AL amyloidosis
Richard Specter et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Renal transplantation in light chain amyloidosis: coming out of the cupboard
Frank Bridoux et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation
Sandra M. S. Herrmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Dense Deposit Disease Associated With Monoclonal Gammopathy of Undetermined Significance
Sanjeev Sethi et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2010)
Solid Organ Transplantation in AL Amyloidosis
P. T. Sattianayagam et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2010)
Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study
Franco Dammacco et al.
BLOOD (2010)
Rituximab plus Peg-interferon-α/ribavirin compared with Peg-interferon-α/ribavirin in hepatitis C-related mixed cryoglobulinemia
David Saadoun et al.
BLOOD (2010)
A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT
M. Ando et al.
BONE MARROW TRANSPLANTATION (2010)
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Recurrent membranoproliferative glomerulonephritis after kidney transplantation
Elizabeth C. Lorenz et al.
KIDNEY INTERNATIONAL (2010)
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Karl Bodin et al.
NATURE (2010)
Crystal-storing histiocytosis with renal Fanconi syndrome: pathological and molecular characteristics compared with classical myeloma-associated Fanconi syndrome
Chahrazed El Hamel et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathway
Jianru Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
How I treat multiple myeloma in younger patients
A. Keith Stewart et al.
BLOOD (2009)
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Donna E. Reece et al.
BLOOD (2009)
Treatment of light chain deposition disease with bortezomib and dexamethasone
Efstathios Kastritis et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Proliferative Glomerulonephritis with Monoclonal IgG Deposits
Samih H. Nasr et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Bortezomib Successfully Reverses Early Recurrence of Light-Chain Deposition Disease in a Renal Allograft: A Case Report
Z. Kaposztas et al.
TRANSPLANTATION PROCEEDINGS (2009)
Heart transplantation in systemic (AL) amyloidosis: A retrospective study of eight French patients
Aude Mignot et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2008)
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease
H. Hassoun et al.
BONE MARROW TRANSPLANTATION (2008)
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
D. Lebovic et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
Ashutosh D. Wechalekar et al.
HAEMATOLOGICA (2008)
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
J. F. San-Miguel et al.
LEUKEMIA (2008)
Long-term outcome of autologous stem cell transplantation in light chain deposition disease
Elizabeth C. Lorenz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
Nionhang Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
Asher A. Chanan-Khan et al.
BLOOD (2007)
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2007)
Immunoglobulin light (heavy)-chain deposition disease: From molecular medicine to pathophysiology-driven therapy
Pierre Ronco et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia
David Saadoun et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Immunoglobulin free light chains and solitary plasmacytoma of bone
David Dingli et al.
BLOOD (2006)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation
K. Weichman et al.
BONE MARROW TRANSPLANTATION (2006)
Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis
N Leung et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement
N Leung et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure
LM Knudsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Fanconi's syndrome induced by a monoclonal Vκ3 light chain in Waldenstrom's macroglobulinemia
F Bridoux et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Bortezornib in recurrent and/or refractory multiple myeloma - Initial clinical experience in patients with impaired renal function
S Jagannath et al.
CANCER (2005)
Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure - a retrospective analysis and recommendations for dose adjustment
K Carlson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics
CA Vieira et al.
TRANSPLANTATION (2004)
High dose chemotherapy in light chain or light and heavy chain deposition disease
B Royer et al.
KIDNEY INTERNATIONAL (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation
F Firkin et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2004)
Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma.
CX Ma et al.
BLOOD (2004)
Long-term outcome of renal transplantation in light-chain deposition disease
N Leung et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2004)
Proliferative glomerulonephritis with monoclonal IgG deposits: A distinct entity mimicking immune-complex glomerulonephritis
SH Nasr et al.
KIDNEY INTERNATIONAL (2004)
Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features
JL Rosenstock et al.
KIDNEY INTERNATIONAL (2003)
Light chain deposition disease with renal involvement: Clinical characteristics and prognostic factors
C Pozzi et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2003)
Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features
F Bridoux et al.
KIDNEY INTERNATIONAL (2002)
Renal involvement in monoclonal (type I) cryoglobulinemia:: Two cases associated with IgG3κ cryoglobulin
A Karras et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2002)
Treatment of a patient with end-stage renal disease with rituximab: Pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis
AP Jillella et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: A prospective dose adjustment study
SM Lichtman et al.
CANCER INVESTIGATION (2002)
Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI
TM Holm et al.
BLOOD (2002)
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
A Badros et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Cryoglobulinemia -: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center
O Trejo et al.
MEDICINE (2001)
Adult Fanconi syndrome secondary to light chain gammopathy - Clinicopathologic heterogeneity and unusual features in 11 patients
T Messiaen et al.
MEDICINE (2000)
Share Paper
